Logo image of INTS

INTENSITY THERAPEUTICS INC (INTS) Stock Fundamental Analysis

NASDAQ:INTS - Nasdaq - US45828J1034 - Common Stock - Currency: USD

0.4148  +0.01 (+3.42%)

Premarket: 0.41 0 (-1.16%)

Fundamental Rating

2

Overall INTS gets a fundamental rating of 2 out of 10. We evaluated INTS against 561 industry peers in the Biotechnology industry. INTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INTS had negative earnings in the past year.
INTS had a negative operating cash flow in the past year.
INTS had negative earnings in each of the past 5 years.
In the past 5 years INTS always reported negative operating cash flow.
INTS Yearly Net Income VS EBIT VS OCF VS FCFINTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

INTS's Return On Assets of -340.12% is on the low side compared to the rest of the industry. INTS is outperformed by 95.54% of its industry peers.
INTS has a worse Return On Equity (-557.51%) than 80.39% of its industry peers.
Industry RankSector Rank
ROA -340.12%
ROE -557.51%
ROIC N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INTS Yearly ROA, ROE, ROICINTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

INTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INTS Yearly Profit, Operating, Gross MarginsINTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for INTS has been increased compared to 1 year ago.
INTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INTS Yearly Shares OutstandingINTS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
INTS Yearly Total Debt VS Total AssetsINTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -28.55, we must say that INTS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -28.55, INTS is not doing good in the industry: 91.09% of the companies in the same industry are doing better.
There is no outstanding debt for INTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.55
ROIC/WACCN/A
WACCN/A
INTS Yearly LT Debt VS Equity VS FCFINTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

A Current Ratio of 1.92 indicates that INTS should not have too much problems paying its short term obligations.
INTS's Current ratio of 1.92 is on the low side compared to the rest of the industry. INTS is outperformed by 77.18% of its industry peers.
INTS has a Quick Ratio of 1.92. This is a normal value and indicates that INTS is financially healthy and should not expect problems in meeting its short term obligations.
INTS has a Quick ratio of 1.92. This is in the lower half of the industry: INTS underperforms 75.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
INTS Yearly Current Assets VS Current LiabilitesINTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

INTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.03%, which is quite impressive.
EPS 1Y (TTM)49.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INTS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.25% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.55%
EPS Next 2Y11.81%
EPS Next 3Y3.74%
EPS Next 5Y20.25%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INTS Yearly Revenue VS EstimatesINTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
INTS Yearly EPS VS EstimatesINTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INTS Price Earnings VS Forward Price EarningsINTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INTS Per share dataINTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.81%
EPS Next 3Y3.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTENSITY THERAPEUTICS INC

NASDAQ:INTS (5/20/2025, 8:05:57 PM)

Premarket: 0.41 0 (-1.16%)

0.4148

+0.01 (+3.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners18.13%
Inst Owner Change-4.65%
Ins Owners38.39%
Ins Owner Change0%
Market Cap6.33M
Analysts81.82
Price Target9.49 (2187.85%)
Short Float %1.92%
Short Ratio1.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.68%
Min EPS beat(2)3.71%
Max EPS beat(2)19.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.75%
EPS NY rev (1m)0%
EPS NY rev (3m)10.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.17
P/tB 2.17
EV/EBITDA N/A
EPS(TTM)-1.05
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -340.12%
ROE -557.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -28.55
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.29%
EPS Next Y26.55%
EPS Next 2Y11.81%
EPS Next 3Y3.74%
EPS Next 5Y20.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-73.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-111.24%
OCF growth 3YN/A
OCF growth 5YN/A